胰腺癌是一种高度致命的疾病，通常在晚期才被诊断出来，其 5 年总生存率约为 10%。目前的治疗方法效果有限，强调需要新的治疗选择。本次范围界定综述旨在确定和总结 FGFR（成纤维细胞生长因子受体）抑制剂（包括酪氨酸激酶抑制剂 (TKI) 和 FGFR 特异性抑制剂）在 FGFR 改变的胰腺癌中的临床前和临床研究。我们纳入了分析不同人群的疗效、安全性和生存结果的研究。对主要数据库的全面检索确定了 73 项相关研究：32 项临床前研究、16 项临床研究和 25 项灰色文献研究。临床试验主要关注疗效（20 项研究）和安全性（14 项研究），涉及生存结果的研究较少。 FGFR1 是研究最多的改变，其次是 FGFR2 和 FGFR4。尽管 FGFR 改变在胰腺癌中相对罕见，但现有数据（包括有希望的现实生活结果）表明 FGFR 抑制剂具有巨大潜力。然而，需要更广泛的研究来确定正确的遗传驱动因素并收集可靠的生存数据。正在进行和未来的试验预计将提供更全面的见解，有可能改善 FGFR 改变的胰腺癌患者的靶向治疗。

Pancreatic cancer is a highly lethal disease, often diagnosed at advanced stages, with a 5-year overall survival rate of around 10%. Current treatments have limited effectiveness, underscoring the need for new therapeutic options. This scoping review aims to identify and summarize preclinical and clinical studies on FGFR (Fibroblast Growth Factor Receptor) inhibitors, including tyrosine kinase inhibitors (TKIs) and FGFR-specific inhibitors, in pancreatic cancer with FGFR alterations. We included studies analyzing efficacy, safety, and survival outcomes in various populations. A comprehensive search across major databases identified 73 relevant studies: 32 preclinical, 16 clinical, and 25 from gray literature. The clinical trials focused primarily on efficacy (20 studies) and safety (14 studies), with fewer studies addressing survival outcomes. FGFR1 was the most studied alteration, followed by FGFR2 and FGFR4. Although FGFR alterations are relatively rare in pancreatic cancer, the available data, including promising real-life outcomes, suggest significant potential for FGFR inhibitors. However, more extensive research is needed to identify the correct genetic drivers and gather robust survival data. Ongoing and future trials are expected to provide more comprehensive insights, potentially leading to improved targeted therapies for pancreatic cancer patients with FGFR alterations.